Could less be more? new study tests shorter hospital stays after stem cell transplants
NCT ID NCT03317899
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one that got the drug and one that did not, to see if the no-drug group could be discharged just as fast. The goal is to simplify treatment and reduce time in the hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tbo-filgrastim (a drug to boost white blood cells)
- What this could lead to
- If successful, this could simplify post-transplant care and reduce hospital stays for patients with multiple myeloma or non-Hodgkin lymphoma.
- What could go wrong
- This is a small, early-phase trial (77 participants) and results may not apply to all patients. Skipping the drug might delay recovery or cause complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug's real-world performance match clinical trial results?
- Supercharged immune cells take aim at cancer and viruses in one shot
- Can a maintenance drug keep myeloma at bay?
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Gut bacteria may hold key to chemo side effects
- New hope for frail myeloma patients: phase III trial tests smarter drug combos